Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.

This publication has 53 references indexed in Scilit:

• Racial variability in the UDP-glucuronosyltransferase 1 ( UGT1A1 ) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
  Proceedings of the National Academy of Sciences, 1998
• A tellurite-resistance genetic determinant from phytopathogenic pseudomonads encodes a thiopurine methyltransferase: evidence of a widely-conserved family of methyltransferases
  Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1998
• Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
  New England Journal of Medicine, 1998
• Detection of known and new mutations in the thiopurineS-methyltransferase gene by single-strand conformation polymorphism analysis
  Human Mutation, 1998
• Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*
  Clinical Pharmacology & Therapeutics, 1997
• Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.
  1995
• Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation
  The Lancet, 1995
• Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA.
  1993
• Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.
  Journal of Clinical Investigation, 1993
• Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1978